Literature DB >> 17723971

Lenalidomide: a new agent for patients with relapsed or refractory multiple myeloma.

Joseph D Tariman1.   

Abstract

Lenalidomide is a potent, novel thalidomide analog that has demonstrated promising clinical activity in patients with relapsed or refractory multiple myeloma (MM). It is a lead immunomodulatory drug currently approved by the U.S. Food and Drug Administration. Neutropenia, thrombocytopenia, and thromboembolic events are common adverse effects associated with lenalidomide therapy in patients with MM. Careful monitoring of those known serious adverse effects is essential to prevent life-threatening complications. This article discusses lenalidomide's mechanisms of action, clinical trial results, and the management of common adverse effects in patients with MM.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17723971     DOI： 10.1188/07.CJON.569-574

Source DB:  PubMed          Journal:  Clin J Oncol Nurs        ISSN： 1092-1095            Impact factor:   1.027


  8 in total

1.  Anti-β₂M monoclonal antibodies kill myeloma cells via cell- and complement-mediated cytotoxicity.

Authors:  Mingjun Zhang; Jianfei Qian; Yongsheng Lan; Yong Lu; Haiyan Li; Bangxing Hong; Yuhuan Zheng; Jin He; Jing Yang; Qing Yi
Journal:  Int J Cancer       Date:  2014-02-07       Impact factor: 7.396

2.  Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.

Authors:  Shaji Kumar; Philippe Moreau; Parameswaran Hari; Maria-Victoria Mateos; Heinz Ludwig; Chaim Shustik; Tamas Masszi; Andrew Spencer; Roman Hájek; Kenneth Romeril; Irit Avivi; Anna M Liberati; Monique C Minnema; Hermann Einsele; Sagar Lonial; Deborah Berg; Jianchang Lin; Neeraj Gupta; Dixie-Lee Esseltine; Paul G Richardson
Journal:  Br J Haematol       Date:  2017-05-09       Impact factor: 6.998

Review 3.  Mechanism of action of lenalidomide in hematological malignancies.

Authors:  Venumadhav Kotla; Swati Goel; Sangeeta Nischal; Christoph Heuck; Kumar Vivek; Bhaskar Das; Amit Verma
Journal:  J Hematol Oncol       Date:  2009-08-12       Impact factor: 17.388

4.  Biological activity of lenalidomide and its underlying therapeutic effects in multiple myeloma.

Authors:  Roberta Martiniani; Valentina Di Loreto; Chiara Di Sano; Alessandra Lombardo; Anna Marina Liberati
Journal:  Adv Hematol       Date:  2012-08-02

5.  Synthesis of hapten and preparation of specific polyclonal antibody with high affinity for lenalidomide, the potent drug for treatment of multiple myeloma.

Authors:  Ibrahim A Darwish; Nourh Z Alzoman; Reem M Abuhejail; Tilal E El-Samani
Journal:  Chem Cent J       Date:  2012-10-26       Impact factor: 4.215

6.  A highly sensitive fluorimetric method for determination of lenalidomide in its bulk form and capsules via derivatization with fluorescamine.

Authors:  Ibrahim A Darwish; Nasr Y Khalil; Ahmed H Bakheit; Nourh Z Alzoman
Journal:  Chem Cent J       Date:  2012-10-16       Impact factor: 4.215

7.  Development and validation of ultra-performance liquid chromatographic method with tandem mass spectrometry for determination of lenalidomide in rabbit and human plasma.

Authors:  Muzaffar Iqbal; Tanveer A Wani; Nasr Y Khalil; Ibrahim A Darwish
Journal:  Chem Cent J       Date:  2013-01-14       Impact factor: 4.215

8.  Trace determination of lenalidomide in plasma by non-extractive HPLC procedures with fluorescence detection after pre-column derivatization with fluorescamine.

Authors:  Nasr Y Khalil; Ibrahim A Darwish; Tanveer A Wani; Abdel-Rahman A Al-Majed
Journal:  Chem Cent J       Date:  2013-03-14       Impact factor: 4.215
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.